Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition

Intensive Care Medicine

Volumn 38, Issue 4, 2012, Pages 642-648

  Cheng, Sara S ^a   Nordenholz, Kristen ^a   Matero, David ^a   Pearlman, Nathan ^a   McCarter, Martin ^a   Gajdos, Csaba ^a   Hamiel, Christine ^a   Baer, Angela ^a   Luzier, Elizabeth ^a   Tran, Zung Vu ^a   Olson, Timothy ^a   Queensland, Kelly ^a   Lutz, Ryan ^a   Wischmeyer, Paul ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Cancer; Intensive care unit; Prophylaxis Sonoclot; Surgery; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN;

ABDOMINAL SURGERY; ADULT; AGED; ANALYZER; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; EPIDURAL HEMATOMA; FEMALE; HUMAN; INHIBITION KINETICS; INTENSIVE CARE; MAJOR SURGERY; MALE; NEOPLASM; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PAIN; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VENOUS THROMBOEMBOLISM; VISCOELASTICITY;

ANALYSIS OF VARIANCE; ANTICOAGULANTS; APACHE; BLOOD COAGULATION TESTS; FACTOR XA; FEMALE; HEPARIN; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84862580031     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-011-2453-4     Document Type: Article

References (20)

1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidencebased clinical practice guidelines (8th edition). Chest 133:381S-453S
2. Geerts W, Selby R (2003) Prevention of venous thromboembolism in the ICU. Chest 124:357S-363S
3. Leizorovicz A, Mismetti P (2004) Preventing venous thromboembolism in medical patients. Circulation 110:IV13-IV19
4. Phung OJ, Kahn SR, Cook DJ, Murad MH (2011) Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest 140:374-381
5. The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group(2011) Dalteparin versus unfractionated heparin in critically Ill patients. N Engl J Med 364:1305-1314
6. Zalpour A, Kroll MH, Afshar-Kharghan V, Yusuf SW, Escalante C (2011) Role of factor Xa inhibitors in cancerassociated thrombosis: any new data? Adv Hematol 2011:196135
7. Cook DJ, Crowther MA (2010) Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients. Crit Care Med 38:S76-S82
8. Fries D (2011) Thrombosis prophylaxis in critically ill patients. Wien Med Wochenschr 161:68-72
9. Mayr AJ, Dunser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W (2002) Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 105:201-204
10. Robinson S, Zincuk A, Strom T, Larsen TB, Rasmussen B, Toft P (2010) Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 14:R41
11. Brancazio LR, Roperti KA, Stierer R, Laifer SA (1995) Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 173:1240-1245
12. Gallus AS, Hirsh J, Tutle RJ, Trebilcock R, O'Brien SE, Carroll JJ, Minden JH, Hudecki SM (1973) Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 288:545-551
13. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L (2000) Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The association of non-university affiliated intensive care specialist physicians of France. Am J Respir Crit Care Med 161:1109-1114
14. Cade JF (1982) High risk of the critically ill for venous thromboembolism. Crit Care Med 10:448-450
15. Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305-1314
16. Bergqvist D, Lindblad B (1985) A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg 72:105-108
17. Rommers MK, Van der Lely N, Egberts TC, van den Bemt PM (2006) Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care 10:R93
18. Zenahlikova Z, Kvasnicka J, Kudrnova Z, Sudrova M, Brzezkova R, Mazoch J, Malikova I, Vyborny J, Erhart D, Pecen L (2009) FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients. Clin Appl Thromb Hemost 16:584-590
19. Dorffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Buller HR, Levi M (2002) Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359:849-850
20. Ganter MT, Hofer CK (2008) Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 106:1366-1375